Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.
The company's lead product is the combination of Ameluz;, a topical prescription drug, and medical device BF-RhodoLED; for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz; has been marketed in the EU since 2012 and in the United States since May 2016.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Luebbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.
1997
Served areaWorldwide
Headcount149
HeadquartersHemmelrather Weg 201, 51377 Leverkusen – Germany
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
24.03.23 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 7,366.00 |
24.03.23 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 381.00 |
20.03.23 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 7,503.16 |
13.03.23 | NEON Equity AG | Close relation | Buy | EUR 30,627.00 |
13.03.23 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 6,290.31 |
13.03.23 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 635.00 |
13.03.23 | TO Holding 1 GmbH | Close relation | Buy | EUR 575.00 |
10.03.23 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 6,718.30 |
08.03.23 | Adenauer, Dr. Sven-Georg | Other | Buy | EUR 140,000.00 |
06.03.23 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 152.40 |
DE0006046113
LEI391200D6GFSVFGFQTL13
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryICF Bank AG
Listed Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.